Pages that link to "Q45987534"
Jump to navigation
Jump to search
The following pages link to Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. (Q45987534):
Displaying 15 items.
- Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer (Q26865779) (← links)
- Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy (Q28081735) (← links)
- Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer (Q35256618) (← links)
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer (Q38242086) (← links)
- mTOR pathway: A current, up-to-date mini-review (Review). (Q38264125) (← links)
- Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review (Q38515841) (← links)
- mTORC1 and mTORC2 in cancer and the tumor microenvironment (Q38982579) (← links)
- Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. (Q39220897) (← links)
- Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma (Q39773825) (← links)
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor (Q41189355) (← links)
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers (Q41908997) (← links)
- Understanding and targeting resistance mechanisms in NSCLC. (Q46915997) (← links)
- Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. (Q55314894) (← links)
- Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (Q89599313) (← links)
- Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma (Q91974823) (← links)